Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.

In this video, the humorous side of dining at Olive Garden is explored through the lens of the waitstaff. It showcases the ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk has appointed Maziar Mike Doustdar as President and CEO, effective August 7, 2025. Doustdar succeeds Lars ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...

Measures intended to punish elite universities are inflicting collateral damage on the nation’s two-year colleges, which ...